Outlier test for reference replicate crossover study design [Regulatives / Guidelines]

posted by ElMaestro  – Belgium?, 2019-08-13 15:28  – Posting: # 20495
Views: 498

Hi Abhimanyu,

» I have question regarding outlier test (Using Lund's method) for reference replicate crossover study design.

Sounds like a bad idea.

» How can we find outlier? which one will be appropriate scenario for any regulatory point of view?

The trick is to avoid generating outliers. In my small universe, there is no problem that merits a solution involving identification and and removal of outliers.

I could be wrong, but...
Best regards,
ElMaestro

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,892 posts in 4,215 threads, 1,364 registered users;
online 10 (0 registered, 10 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 00:09 CEST

A drug is not bad. A drug is a chemical compound.
The problem comes in when people who take drugs treat them
like a license to behave like an asshole.    Frank Zappa

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5